Bardoxolone methyl
Bardoxolone methyl, previously known as RTA 402, is the lead molecule in Reata's portfolio of AIMs
LEARN MORE »
Reata is a biopharmaceutical company that focuses on novel approaches to intractable diseases that have the greatest chance generating substantial improvements in the lives of patients affected by such diseases.